Immunotherapy Cycles Explained: Why Infusions Repeat Every Few Weeks and for How Long

The appointment letter arrives with a grid on the back: a date circled every three weeks, stretching across more pages than feels reasonable. Somebody at the kitchen table does the arithmetic out loud. Seventeen visits. Then a question nobody in the room can answer: why that many, and why that gap?

An immunotherapy treatment schedule looks arbitrary from the outside. The intervals seem round, the end point seems far away, and the chemotherapy a neighbor had followed an entirely different rhythm. In fact, almost every number on that grid traces back to something measurable: how fast a drug leaves the bloodstream, how long a reactivated immune cell keeps working, and what the large trials that tested the medicine actually did.

This explainer walks through that logic in plain language, from the first infusion to the conversation about stopping, so the grid on the back of the letter starts to make sense.

What an immunotherapy treatment schedule actually describes

Three words do most of the work in any oncology calendar: cycle, infusion and rest. A cycle is one complete round of treatment, counted from the day a drug is given to the day before the next one. The infusion is the part you sit through in a chair. The rest is everything in between, when nothing is being administered but a great deal is still happening inside you.

The National Cancer Institute describes immunotherapy as being given in cycles for many patients, meaning a period of treatment followed by a period of rest that lets the body respond and recover. Put several cycles together and you have what clinicians call a treatment schedule or regimen: the drug or drugs, the route, the interval and the planned duration, written down before the first appointment.

Why does the schedule matter beyond logistics? Because immunotherapy does not work the way most people picture medicine working. A painkiller acts while it is in the bloodstream and stops when it leaves. Checkpoint inhibitors, the most widely used class of cancer immunotherapy, do something less direct. They release a brake on the immune system and then step back. The immune cells they unlock may keep working long after the drug itself has gone. The schedule is designed to keep the brake off reliably without flooding the body with more medicine than it can use.

Three features show up in nearly every immunotherapy treatment schedule for solid tumors. The interval between infusions is fixed in advance. The infusion itself is relatively brief. And the total duration is measured in months rather than weeks, often with a built-in review point. Each of those features has a reason, and the rest of this article takes them one at a time.

How checkpoint inhibitors work, and why the clock starts at the first infusion

Picture a T cell, one of the immune system’s patrol officers, bumping into a cancer cell. In a healthy response, the T cell recognizes trouble and attacks. Many tumors have learned a trick: they display a protein that fits into a receptor on the T cell’s surface and tells it to stand down. That receptor is a checkpoint, a natural safety switch that normally stops the immune system from attacking the body’s own tissue.

Checkpoint inhibitors are antibodies, large laboratory-made proteins, that physically block that handshake. According to the National Cancer Institute, the common targets are PD-1 and PD-L1 (the receptor and the protein that fits it) and CTLA-4 (a second brake that acts earlier in the immune response). Block the handshake and the T cell may resume its attack.

Here is where timing enters. An antibody drug circulates for a long time compared with a tablet, but it is still gradually removed and recycled by the body. If the brake is to stay off, the drug level has to be topped up before it falls too far. That top-up interval, worked out in early studies that measured drug levels in blood over days and weeks, becomes the cycle length.

There is a second clock running alongside the first. Once T cells are released, they need time to multiply, travel to the tumor and do their work. The rest period in each cycle is not dead time; it is when most of the biological action happens. Cleveland Clinic notes that immunotherapy can take longer than chemotherapy to show visible results on scans precisely because the drug is recruiting the immune system rather than killing cells directly.

So the first infusion sets two things in motion: a falling drug level that will be replenished on a fixed day, and an immune process that will be assessed over months.

How long does a session of immunotherapy take?

Less time than most people brace for. The infusion itself, meaning the period the drug is actually running into a vein, is commonly measured in tens of minutes rather than hours for the main checkpoint inhibitor antibodies. Cleveland Clinic describes immunotherapy infusion visits as typically shorter than many chemotherapy sessions, and the National Cancer Institute lists intravenous infusion as the most common route, alongside oral, topical and bladder-instilled forms for specific cancers.

The full visit is longer than the infusion. A realistic timeline for a single appointment usually includes:

• Check-in and a blood draw, because the results decide whether treatment can go ahead that day.
• A review with a nurse or clinician covering new symptoms since the last cycle, with particular attention to breathing, bowel habit, skin and energy.
• Waiting for the pharmacy to prepare the drug once bloods are cleared; antibody drugs are prepared individually and cannot be made up in advance.
• The infusion, followed by a short observation period during the first few cycles to watch for an infusion reaction.

Add those together and a half day is a sensible expectation for early visits, often less once a person is established on treatment and the team is confident there is no reaction. Some centers run bloods a day or two ahead to shorten the chair time.

Infusion reactions, meaning flushing, chills, itching or a change in blood pressure during or shortly after the drip, are less common with checkpoint inhibitors than with some older antibody drugs, but nurses still watch for them, which is why the first sessions are deliberately unhurried. If a reaction occurs, the usual response is to slow or pause the infusion and treat the symptoms; the decision about continuing sits with the treating team.

One practical consequence follows from all this: if someone asks how long immunotherapy takes, the honest answer has two parts. The drip is short. The commitment is long.

Why immunotherapy is given every 3 weeks, or every 2, 4 or 6

The interval is the question that puzzles people most, and the answer is partly chemistry and partly history. Each checkpoint inhibitor was first studied at a particular interval chosen to match how long the drug stayed active in blood. Later studies tested whether a larger amount given less often would keep the brake off just as reliably. Where it did, regulators approved the longer interval as well. That is why a single drug may be listed as given every two weeks, every three weeks, every four weeks or every six weeks, depending on the cancer and the regimen, and why two people with the same diagnosis can be on different rhythms.

Three weeks became a common default for a practical reason too. It matches the interval of many chemotherapy regimens, so when immunotherapy is combined with chemotherapy, both can be given on the same day. The Cleveland Clinic overview of immunotherapy notes that it is frequently paired with chemotherapy, targeted therapy or radiation, and a shared cycle length keeps the calendar manageable.

Combination regimens add their own wrinkle. Chemotherapy is often given for a fixed number of cycles at the start, sometimes four to six, and then stopped while the immunotherapy continues alone as maintenance. The schedule on paper may therefore change shape partway through, with the same visit day but fewer drugs in the bag. Some teams also move the immunotherapy to a longer interval at that point, if an approved longer interval exists for that drug.

What the interval is not: a measure of how serious the cancer is, or how well treatment is going. Someone on a six-week schedule is not doing better or worse than someone on a three-week schedule. They are simply on a regimen whose drug-level studies supported that gap.

The interval is also not something to compress or stretch for convenience. Arriving a few days late for a cycle is usually tolerated and rescheduled. Skipping or doubling cycles is a clinical decision, not a calendar one.

How many cycles of immunotherapy are needed?

There is no single normal number, and anyone who tells you otherwise is guessing. The count depends on the cancer, the drug, the interval and, above all, the reason the treatment is being given. It helps to separate the question into three situations.

When immunotherapy is given before surgery (neoadjuvant, meaning treatment intended to shrink or weaken a tumor ahead of an operation), the number of cycles is usually small and fixed in advance, so the operation is not delayed longer than planned. When it is given after surgery (adjuvant, meaning treatment intended to reduce the chance of the cancer returning), protocols typically run for a set period of around a year, with the cycle count following from the interval.

When immunotherapy is the main treatment for cancer that has spread, the plan is more open-ended. Treatment usually continues as long as scans show it is helping and side effects stay manageable, up to a predefined maximum. In the five-year follow-up of a large lung cancer trial published in the Journal of Clinical Oncology, treatment in the immunotherapy arm was planned for up to 35 cycles given every three weeks, roughly two years, and some participants who completed that course remained off treatment at the time of reporting. That trial design, with a two-year ceiling, shaped many regimens that followed.

So a person on a three-week schedule for advanced disease might see a calendar with 35 slots. A person on an adjuvant one-year schedule at six-week intervals might see nine. Both are normal for their situation.

What matters more than the total is the review built into the plan. Most schedules include an early assessment after a few cycles, when the team decides whether to continue. A high planned number is a ceiling, not a target that must be reached.

What is the typical treatment timeline for immunotherapy?

Laying the pieces side by side makes the pattern easier to see. The table below summarizes typical shapes of immunotherapy treatment schedules. Every figure is a common range drawn from the National Cancer Institute’s descriptions of immunotherapy administration and from published trial protocols, not a prediction for any individual.

Setting	Usual interval between infusions	Typical planned duration	What decides the end point
Before surgery (neoadjuvant)	Every 2–3 weeks	A few cycles, fixed in advance	The surgery date
After surgery (adjuvant)	Every 2–6 weeks	Around 1 year	Completing the planned course, or side effects
Main treatment for advanced cancer	Every 2–6 weeks	Until progression or unacceptable side effects, often capped at about 2 years	Scans, side effects, shared decision
Combined with chemotherapy	Usually every 3 weeks to match chemo	Chemo for a fixed number of cycles, immunotherapy continues	Same as above
Cell therapies such as CAR T	Not cyclical	A single infusion after preparation	Monitoring rather than repeat dosing

Two rows deserve a note. Cell therapies, in which a patient’s own immune cells are collected, modified and returned, do not follow a cycle at all; the National Cancer Institute describes them as a one-time infusion preceded by preparatory treatment and followed by close monitoring. They are mentioned here because people often lump all immunotherapy together, and the schedules could hardly be more different.

The other is the advanced-cancer row. Until progression means that treatment continues as long as scans do not show the cancer growing. The two-year cap in many regimens comes from how the pivotal trials were designed, as in the lung cancer study cited earlier, rather than from a biological rule that the immune system switches off at that point. Whether to continue beyond it, pause, or stop earlier is one of the most active questions in oncology, and the following sections explain how teams approach it.

Who is usually offered immunotherapy, and who is asked to wait

Eligibility is not about optimism or fitness alone. It rests on a short list of questions the team answers before anyone is booked into a chair.

Does this cancer type respond to immune checkpoint blockade? The National Cancer Institute lists a growing group of cancers for which checkpoint inhibitors are approved, including several lung, skin, kidney, bladder, head and neck, and some gastrointestinal cancers, and tumors with particular genetic features regardless of where they started. Many other cancers do not yet have evidence of benefit, and in those cases immunotherapy is usually offered only within a clinical trial.

Does the tumor carry markers that predict a response? For several cancers, a laboratory test on the biopsy measures how much PD-L1 the tumor displays, or whether it has a high mutation burden or a mismatch-repair defect. These results influence whether immunotherapy is given alone, with chemotherapy, or not at the current stage.

Is the immune system in a position to be released safely? This is where waiting enters. People with active autoimmune disease, those taking immune-suppressing medicines after an organ transplant, and those who have recently had a serious immune-related reaction are often asked to wait or to consider other treatments, because unlocking the immune system can worsen the underlying condition. The decision is individual; some people with controlled autoimmune disease do receive treatment under close monitoring.

Is now the right moment in the overall plan? Someone about to have surgery or radiation may have immunotherapy timed around those procedures rather than started immediately. Someone with an uncontrolled infection will usually be asked to wait until it has settled. A delay in these situations is not a lost opportunity; it is sequencing.

Every one of these judgments belongs to the treating team, who weigh the tumor biology, the person’s other health conditions and the available alternatives together.

What the days after an infusion usually look like

Most people are surprised by how ordinary the first day or two feel. There is no hair loss to anticipate and, for immunotherapy given alone, nausea is far less common than with chemotherapy. The National Cancer Institute lists tiredness, flu-like symptoms, skin changes and aches as among the more frequent early effects, and many people describe the evening after an infusion as a heavy, flat feeling rather than acute illness.

A loose pattern, which varies enormously between individuals:

• Days one to two: fatigue is the headline. Some people notice chills or mild aches, as if fighting off a cold. Drinking normally and resting when tired is reasonable; pushing through a planned workout is not required.
• Days three to seven: for many, energy drifts back toward baseline. Skin may feel dry or itchy, and a faint rash can appear and fade.
• The rest of the cycle: often unremarkable, which is why people frequently keep working or travelling between infusions.

The quiet stretch is also when immune-related side effects can first surface, and the whole point of the symptom review at the next appointment is to catch them. Cleveland Clinic and the National Cancer Institute both emphasize that immunotherapy side effects differ from chemotherapy because they arise from the immune system attacking healthy tissue, so the warning signs are organ-specific: diarrhea that persists, a new cough or breathlessness, headaches with unusual tiredness, or yellowing of the skin. A later section covers these in detail.

Two routines make the cycle easier. Keep a simple note of symptoms with the date, because a pattern that is obvious on paper is easy to forget in a ten-minute consultation. And ask the team which symptoms they want to hear about immediately rather than at the next visit; most centers give a card or phone number for exactly this.

How your team checks whether the schedule is working

The main tool is imaging, repeated at fixed points in the schedule rather than after every infusion. In the five-year lung cancer trial referenced earlier, scans were scheduled roughly every nine weeks, which works out to every third cycle on a three-week rhythm; many routine protocols follow a similar logic of imaging every few cycles, with the exact interval set by the team.

Reading those scans is less straightforward than with chemotherapy, and the reason is worth knowing. When the immune system is recruited to a tumor, the site can swell with immune cells before it shrinks. On a scan this can look like growth. Clinicians call this pseudoprogression, meaning apparent growth on imaging that is caused by inflammation rather than more cancer. The National Cancer Institute notes that immunotherapy can take longer to show results than other treatments for this reason, and oncologists often confirm a worrying scan with a repeat a few weeks later before changing course, provided the person feels well.

Blood tests do their own quiet work at every visit. Thyroid, liver and kidney function, blood counts and glucose are checked not to measure the cancer but to catch the immune system attacking those organs before symptoms appear. A drifting thyroid result on a routine panel is one of the most common ways an immune-related side effect is first picked up.

Symptoms count as data too. Feeling better, breathing more easily or regaining appetite between cycles is meaningful, though it is not a substitute for a scan. The reverse is also true: new symptoms with stable scans still warrant attention.

What a scan cannot tell anyone is how long to keep going. A stable or shrinking tumor confirms that the plan is working; the decision about continuing, pausing or stopping draws on the whole picture, and the next section explains how that decision tends to be approached.

Pausing, delaying and stopping: how long do you stay on immunotherapy?

Four things can change the schedule once it is underway, and only one of them is bad news.

A delay is the most common. If blood results are off, if a side effect needs time to settle, or if someone has a fever on the day, the team postpones the cycle rather than cancelling it. The National Cancer Institute notes that treatment may be delayed or stopped if side effects become severe. A delay of a week or two is generally not thought to undo the benefit of previous cycles, because the drug and the immune response it has triggered persist well beyond the dosing day.

A pause is a deliberate break, often to treat an immune-related side effect with corticosteroids, a class of anti-inflammatory medicine that dampens the immune response. Whether treatment restarts afterwards depends on how severe the reaction was and which organ was involved; this is a judgment the treating team makes case by case.

A planned stop happens when the schedule reaches its intended end: the adjuvant year is complete, or the two-year ceiling in an advanced-cancer regimen is reached. Here the honest answer about what comes next is that evidence is still developing. In the lung cancer follow-up cited in this article, a proportion of people who completed the planned course remained without progression off treatment, and others who later progressed were able to restart. That is encouraging, and it is also a single trial population; it is not a guarantee for anyone.

The fourth change is stopping because scans show the cancer growing despite treatment. Teams usually confirm this on a repeat scan to rule out pseudoprogression, then discuss other options, which may include a different class of treatment, a clinical trial, or supportive care.

Stopping early because treatment is going well, before the planned end, is a live research question rather than standard practice. Anyone considering it should expect a careful, individual conversation rather than a rule.

What people often get wrong about immunotherapy cycles

Some misunderstandings come up so often that correcting them up front saves a great deal of worry.

More cycles means the cancer is worse. It does not. A long planned course reflects the regimen, not the prognosis. Adjuvant treatment after a completely removed tumor can run for a year; a few neoadjuvant cycles before surgery might be given for a larger tumor. The number carries no verdict.

Immunotherapy is a gentler form of chemotherapy. It is a different mechanism entirely. The National Cancer Institute is clear that immunotherapy works by helping the immune system act against cancer, whereas chemotherapy kills rapidly dividing cells directly. Side effects overlap only partially, and the serious ones with immunotherapy are inflammatory rather than toxic.

Feeling fine means no side effects are happening. Thyroid, liver and adrenal changes often begin silently and are found on blood tests before anyone feels unwell. This is why bloods are drawn every cycle even when a person feels well.

If the first scan looks worse, treatment has failed. Not necessarily. Pseudoprogression, explained above, is a recognized pattern, and teams commonly repeat imaging before concluding that a drug is not working.

Once treatment stops, side effects stop. The National Cancer Institute notes that immune-related side effects can appear weeks or months after treatment ends. The immune system does not reset on the last infusion day, and the monitoring plan should not end there either.

Missing a cycle resets the whole course. A short delay is rescheduled, not restarted. The biological effect of earlier cycles continues during the gap.

Immunotherapy works for every cancer. It is approved for a specific and growing list. For other cancers, the evidence may be absent, mixed, or limited to trials, and an honest team will say so.

Side effects run on their own calendar

Here is the part of the immunotherapy treatment schedule nobody prints on the appointment grid. Side effects from checkpoint inhibitors do not cluster neatly in the days after an infusion the way chemotherapy nausea does. They follow the immune system’s timing, which is slower, less predictable and organ by organ.

The mechanism explains the pattern. Releasing the brake on T cells does not aim them only at cancer. The same cells can turn on healthy tissue, producing inflammation that clinicians label by the organ involved: colitis in the bowel, pneumonitis in the lungs, hepatitis in the liver, thyroiditis or hypophysitis in hormone-producing glands, dermatitis in the skin. The National Cancer Institute’s guidance on immunotherapy side effects lists these among the recognized immune-related effects, along with fatigue, joint pain and, rarely, inflammation of the heart or nervous system.

Timing varies by organ. Skin changes often appear within the first few cycles. Bowel and liver inflammation tend to emerge after several cycles. Hormone gland effects, particularly thyroid changes, can surface months in, and some do not resolve even when treatment ends, requiring long-term hormone replacement. The National Cancer Institute specifically notes that immune-related side effects may begin after treatment has finished.

Severity ranges widely. Many effects are mild and managed with creams, simple medicines or a watchful pause. More serious inflammation is usually treated with corticosteroids to calm the immune response, and the treating team decides whether and when immunotherapy can resume. The reassuring point is that most immune-related effects respond to prompt treatment, and prompt treatment depends on early reporting, which is why the symptom review at every visit is not a formality.

Monitoring, therefore, should be thought of as part of the schedule itself: bloods at every cycle, a symptom conversation at every cycle, and a clear plan for who to contact between cycles. That plan continues after the final infusion for as long as the team advises.

Questions to ask your care team about your schedule

A good schedule conversation is specific. These questions tend to produce useful answers, and writing them down before the appointment helps when the room feels rushed.

• Which drug or drugs am I receiving, and is this immunotherapy alone or combined with chemotherapy or another treatment?
• How often will the infusions be, and why that interval for my regimen?
• How long is each visit likely to take at the start, and will that change once I am established?
• How many cycles are planned, and is that a fixed course or a ceiling that depends on how I respond?
• When is the first scan to check progress, and how will you tell real growth from pseudoprogression?
• Which blood tests will be done each cycle, and what are they looking for?
• What symptoms do you want to hear about the same day, and what number do I call, including at night and on weekends?
• If a cycle is delayed, how long a gap is acceptable before it affects the plan?
• If I have a side effect that needs steroids, what usually decides whether treatment restarts?
• What happens at the end of the planned course: stop, pause, or continue, and how will we decide?
• How long will monitoring continue after the last infusion?
• Are there clinical trials relevant to my situation, and would joining one change the schedule?

Two habits make the answers more useful. Ask the team to write the plan down or point to where it is documented, because a schedule explained verbally in a first appointment is hard to recall accurately a week later. And ask who coordinates changes, so that when a cycle moves or a scan is added, there is one name to contact rather than several departments.

None of these questions second-guess the team. They give the person on the schedule the same map the clinicians are already using.

When to call your doctor

Immune-related side effects are most treatable when they are caught early, and the gap between infusions is exactly when they tend to appear. The guidance below reflects the red-flag symptoms described by the National Cancer Institute and Cleveland Clinic for people receiving checkpoint inhibitors. It is a prompt to call, not a tool for self-diagnosis; the treating team decides what each symptom means.

Contact your treatment team the same day, using the number they gave you, if you notice any of the following between cycles:

• Diarrhea that is new, persistent or increasing, especially with abdominal pain, blood or mucus in the stool.
• A new or worsening cough, shortness of breath, or chest discomfort, even without a fever.
• Yellowing of the skin or eyes, dark urine, pale stools, or pain under the right ribs.
• A fever, chills or feeling generally unwell in a way that is new for you.
• Severe headache, unusual fatigue, dizziness on standing, confusion or changes in vision.
• A widespread rash, blistering, or sores in the mouth.
• New muscle weakness, numbness, tingling, or difficulty swallowing or speaking.
• Palpitations, fainting, or swelling of the legs.
• Marked thirst, frequent urination or unexplained weight change.

Seek emergency care immediately for severe breathing difficulty, chest pain, signs of a stroke, a seizure, or a reaction during or shortly after an infusion with facial swelling, wheeze or a sudden drop in blood pressure.

Two practical points. Tell any clinician you see, including in an emergency department, that you are receiving immunotherapy and when your last infusion was; the treatment for immune-related inflammation differs from the treatment for an ordinary infection. And keep reporting for as long as your team advises after the final cycle, because the National Cancer Institute notes that these effects can first appear after treatment has stopped.

Every decision about delaying, pausing, treating a side effect or continuing the schedule rests with the team looking after you.

Frequently asked questions

How many rounds of immunotherapy are normal?

There is no single normal number because it depends on why treatment is given. A few cycles are typical before surgery, around a year of cycles is common after surgery, and for advanced cancer treatment often continues until scans show progression or side effects become unacceptable, frequently capped at about two years in the trials that defined these regimens. Your team sets the planned count and reviews it at each scan.

How long does a session of immunotherapy take?

The infusion itself is usually brief, often under an hour for the common checkpoint inhibitor antibodies. The whole appointment is longer because it includes a blood draw, a review of symptoms since the last cycle, pharmacy preparation of the drug once bloods are cleared, and a short observation period during early sessions. Planning for a half day at the start is sensible, with visits often shortening later.

What is the typical treatment timeline for immunotherapy?

A typical timeline runs in repeating cycles of two to six weeks, with scans every few cycles to check response and blood tests at every visit to catch silent side effects. Before surgery the course is short and fixed; after surgery it commonly lasts about a year; for advanced cancer it continues as long as it is helping, often up to about two years, with monitoring continuing afterwards.

How many cycles of immunotherapy are needed before you know it is working?

Most teams schedule the first assessment scan after a few cycles, roughly two to three months into treatment, rather than after every infusion. Immunotherapy can take longer than chemotherapy to show visible change because it works through the immune system, and an early scan can look worse due to inflammation. A repeat scan a few weeks later often clarifies the picture before any change is made.

Why is immunotherapy given every 3 weeks for some people and every 6 weeks for others?

The interval reflects how long each drug stays active in the bloodstream and which schedules were tested and approved. Many drugs were first studied every two or three weeks, and later studies showed that a larger amount given less often maintained the same effect, so longer intervals were added. Three weeks is also common because it matches many chemotherapy regimens given alongside immunotherapy.

How long do you stay on immunotherapy if it is working?

For advanced cancer, treatment usually continues while scans show benefit and side effects remain manageable, often up to a planned ceiling of about two years drawn from the major trials. What happens after that point is still being studied; in one five-year lung cancer follow-up, some people who completed the planned course remained off treatment without progression, while others later restarted. The decision is individual and rests with your team.

Does missing or delaying a cycle of immunotherapy reduce its effect?

A short delay of a week or two is common and is generally rescheduled rather than treated as a setback. The antibody drug remains in the body for an extended period and the immune response it has triggered continues during the gap. Delays are often deliberate, to let a side effect settle or to wait out an infection. Your team decides how long a gap is acceptable in your regimen.

Can side effects of immunotherapy appear after the last infusion?

Yes. Immune-related side effects can begin weeks or months after treatment finishes because the immune system does not switch off on the final infusion day. Hormone gland effects, particularly involving the thyroid, are among those that can emerge late and sometimes persist. This is why monitoring and a clear contact plan continue after the planned course ends, for as long as your team advises.

Is a longer immunotherapy treatment schedule a sign that the cancer is more serious?

No. The planned length reflects the regimen and the setting, not the prognosis. Treatment after complete surgical removal of a tumor, intended to lower the chance of recurrence, can run for a year even when no cancer is detectable, while a larger tumor might receive only a few cycles before surgery. The number of planned cycles should be read as a design feature, not a verdict.

Who is usually asked to wait before starting immunotherapy?

People with active autoimmune disease, those on immune-suppressing medicines after an organ transplant, and those with an uncontrolled infection are often asked to wait or to consider other options, because releasing the immune brake can worsen these conditions. Timing around planned surgery or radiation can also lead to a deliberate delay. These are individual judgments made by the treating team, weighing risks against the available alternatives.

References

• Immunotherapy, Cleveland Clinic
• Cancer Immunotherapy, MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.